Introduction to the Investigations
Bragar Eagel & Squire, P.C. is a respected law firm taking a closer look at the activities of Cardlytics, Inc. (NASDAQ: CDLX), Medpace Holdings, Inc. (NASDAQ: MEDP), Customers Bancorp, Inc. (NYSE: CUBI), and Ibotta, Inc. (NYSE: IBTA). Their investigations primarily focus on assessing whether there have been violations of federal securities laws or other unlawful business practices by these companies. This scrutiny is critical for investors who may have been affected by recent developments.
Cardlytics, Inc. Investigation
Recent Challenges Faced by Cardlytics
Cardlytics recently shared its financial performance for the second quarter of 2024, noting a concerning 9% decrease in revenue compared to the previous year, totaling $69.6 million. Additionally, their adjusted contribution also dipped by 3%, bringing it down to $36.4 million. The company experienced a significant leadership change with the departure of CEO Karim Temsamani from his position and the board. Following this news, Cardlytics' stock plummeted by $3.94, representing a staggering 57.10% decline, closing at just $2.96 a share the next day.
Medpace Holdings, Inc. Investigation
Medpace's Financial Results and Impact
Medpace, another company under investigation, released its second quarter earnings report shortly after Cardlytics. Unfortunately, it too fell short of market expectations. In an earnings call, the company acknowledged unusually high cancellations, particularly in June. This had a direct impact on their stock price, which dwindled by $79.88 or 18.3%, finishing at $357.30 per share after the report.
Customers Bancorp, Inc. Investigation
Corporate Governance Issues
Customers Bancorp has also found itself in a challenging situation. The firm recently notified the SEC about the termination of its Executive Vice President and CFO, Carla Leibold, for ‘cause’. This announcement attracted scrutiny after it was revealed that there were disagreements regarding the reasons for her termination. Following this news, the company's stock fell $2.40, reflecting a 4.9% decrease, and continued to struggle in the aftermath with a further decline of $2.71, translating to a 5.47% drop in its share value.
Ibotta, Inc. Investigation
Financial Performance and Market Reaction
Finally, Ibotta shared its second quarter results, indicating a net loss of $34 million. It also reported a significant decline in consumer engagement, with a 19% drop in redemptions. This grim news led to a sharp decline in Ibotta's stock price, which fell by $15.53, representing a staggering 26.7% drop, closing at $42.66 per share.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a law firm that is well-established across the United States. They advocate for the rights of individual and institutional investors and engage in complex litigation, including securities and commercial cases. Their commitment to client advocacy positions them as staunch defenders of investor interests.
Contact Information
If you wish to learn more about these investigations, you can reach out to Bragar Eagel & Squire, P.C. directly. Here’s how to get in touch:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Frequently Asked Questions
What is Bragar Eagel & Squire, P.C. investigating?
The firm is investigating potential claims against Cardlytics, Medpace, Customers Bancorp, and Ibotta regarding possible violations of federal securities laws.
How did Cardlytics' stock react to recent news?
Cardlytics' stock price plummeted 57.10% after it announced unfavorable financial results and leadership changes.
What caused the decline in Medpace's stock price?
Medpace's stock fell due to disappointing financial results and significant cancellations reported in their earnings call.
What were the results of Ibotta's financial report?
Ibotta reported a net loss of $34 million, with a decline in consumer redemptions leading to a 26.7% drop in stock price.
How can I contact Bragar Eagel & Squire, P.C.?
You can reach them by calling (212) 355-4648 or emailing investigations@bespc.com.
